Skip to main content
. Author manuscript; available in PMC: 2016 Aug 31.
Published in final edited form as: Lancet Oncol. 2016 Apr 11;17(5):642–650. doi: 10.1016/S1470-2045(16)00077-2

Figure 2. Response to dabrafenib in BRAF V600E–mutant NSCLC.

Figure 2

Maximum change in the sum of lesion diameters by best confirmed response in ≥ second-line patients treated with dabrafenib (N = 78) at the time of the clinical activity analyses. The dashed line at 20 represents the RECIST 1.1 definition for progressive disease, while the dashed line at −30 represents the definition for partial response. Asterisks represent patients with no change from baseline at the time of assessment. NE denotes not estimable, NSCLC non-small cell lung cancer, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria In Solid Tumors, SD stable disease.